Background: Whereas HAART initiated at CD4 cell counts 351-450 cells/ml reduces mortality, compared with starting at lower CD4 levels, there is currently no evidence for the advantages of initiating treatment at CD4 cell counts greater than 450 cells/ml.
Introduction
There is increasing evidence that starting HAART at higher CD4 cell counts reduces mortality and delays development of AIDS [1] . In a recent analysis [2] , mortality was compared according to CD4 cell count at HAART initiation among adult patients in 18 cohorts in the United States and Europe. In this analysis, deferring HAART until CD4 cell count reached 251-350 cells/ml was associated with a 28% [95% confidence interval (CI) 4-57] higher rate of AIDS and death compared with starting when CD4 cell count was 351-450 cells/ml, but initiating HAART at CD4 cell counts higher than 351-450 cells/ml conferred no significant benefit. The authors concluded that 350 cells/ml should be the minimum threshold for HAART initiation.
Method
We enrolled a cohort of 14 110 postpartum women within 96 h of delivery in Zimbabwe between 1997 and 2000 and followed them for up to 24 months as part of a vitamin A supplementation trial [3] . HAART was not available in the public sector during the time of the trial. At baseline, 4595, 9562, and 53 women tested HIVpositive, negative and indeterminate, respectively, and CD4 cells were counted for HIV-positive women and a representative subsample of 721 HIV-negative women. At baseline, mean CD4 cell count was 436 cells/ml [95% confidence interval (CI) 428-444] and 782 cells/ml 95% CI 759-805) among the HIV-positive and HIV-negative women, respectively. Cause of death was determined from medical records, if available, or by review of verbal autopsy by the study gynecologist, who was masked to treatment group and HIV status; multiple causes were recorded and not ranked. Deaths due to injuries following accidents were excluded from this analysis. As expected, mortality was strongly associated with HIV status (HIVpositive women were 14.2 (8.9-22.6) and 54.1 (13.3-220) times more likely to die in the first and second year postpartum, respectively, compared with HIV-negative women, and among infected women, mortality risk steadily increased with decreasing baseline CD4 cell count [4] . Cause-specific mortality was higher among HIV-positive compared with HIV-negative women for all causes except hypertensive disorders and injuries; risk ratios were highest for HIV-associated causes (e.g., tuberculosis, pneumonia, meningitis), but HIV-positive women were also significantly more likely to die of obstetric causes (e.g., puerperal sepsis, uterine hemorrhage, pelvic inflammatory disease).
In a new analysis, we stratified HIV-positive women into six CD4 cell count groups (<200, 200 < 400, 400 < 600, 600 < 800, 800 < 1000, and >1000 cells/ml). In Cox models adjusting for maternal age, education and marital status, delivery method (caesarean vs. other), survival of a previous child, upper arm circumference, and vitamin A treatment, we compared the 2-year mortality risk of HIVpositive women in each CD4 cell count range with that of all the HIV-negative women enrolled in the trial.
Results
As expected, the hazard ratio was extremely high for HIV-positive women in the lowest CD4 cell strata and sharply declined for each higher CD4 cell count stratum between less than 200 and 400-600 cells/ml ( Fig. 1) .
Unexpectedly, the risk of death remained significantly higher for HIV-positive women across the entire CD4 cell distribution up to 1000 cells/ml, compared with HIVnegative women. Among all HIV-positive women with CD4 cell counts higher than 600 cells/ml [mean 803 cells/ ml (95% CI 790-817), slightly higher than the mean concentration of negative women], mortality between delivery and 24 months postpartum was 6.2 (95% CI: 3.2-11.9) times higher than that in HIV-negative women. Over the first 6 months postpartum, the corresponding hazard ratio was similar at 5.8 (95% CI 2.0-17.1) ( Table 1) .
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AIDS 2010, Vol 24 No 3 Among the HIV-positive women who died, we examined cause of death among those whose baseline CD4 cell count was more than 280 cells/ml. This cut-off was chosen because the mean increase in CD4 cell count between baseline and 6 weeks due to normalizing hydration postpartum among study women was 70 cells/ ml (unpublished data), so 280 cells/ml at delivery approximated those women whose 'true' CD4 cell count was more than 350 cells/ml and would, therefore, not be HAART-eligible by current guidelines. Among this group of women, there were 71 deaths: seven died of unknown causes and two died of injuries. Of the remaining 62 deaths, 31 (50%) were associated with tuberculosis, 15 (24%) with nonobstetric infectious conditions (e.g., acute respiratory infection, meningitis), three (5%) with direct obstetric infectious causes (e.g., puerperal sepsis), three (5%) with malaria, and 10 (16%) with a chronic medical condition (e.g., heart or kidney disease).
Conclusion
These data suggest that (unlike nonpostpartum adults in developed countries) for postpartum women in developing country settings, HIV infection is associated with substantial mortality even in its very early stages. This might be due to the additional morbidity associated with pregnancy [5] , the additional metabolic demands of breastfeeding [6, 7] (90% of HIV-positive women in ZVITAMBO breastfed to 6 months), the physiologic immune suppression of pregnancy and the early postpartum period [8] , or the confluence of all these factors. We have no formal evidence that the observed excess mortality would have been amenable to prevention by early antiretroviral treatment. However, given the beneficial effect of HAART on tuberculosis [9] and assuming HAART may also prevent or reduce case fatality of other infectious diseases, an estimated 50-90% of the deaths observed among these HIV-positive women with high CD4 cell counts in this study may have been averted by early HAART initiation.
This intervention would also benefit their infants. Recent studies have demonstrated that provision of HAART to women with CD4 cell count 350-500 cells/ml from pregnancy up to 6 months postpartum substantially reduces vertical transmission without adverse effects [10] [11] [12] [13] . However, because breastfeeding cessation at 6 months (at the time when antiretroviral treatment is stopped) results in high rates of infant gastroenteritis and mortality [14] , continuing maternal HAART and breastfeeding would likely improve infant HIV-free survival.
Early HAART for pregnant women in developing countries may even benefit their societies. Recent mathematical modeling has suggested that early HAART significantly reduces HIV transmission and, if started soon enough after sero-conversion, may hasten the end of the HIV epidemic [15] .
